Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,683.00+1.28%ETH$2,286.51+1.78%GOLD$3,940.20-0.74%OIL$96.76+0.31%
Smart Investors Daily
SID Premium
TR

NASDAQ · TRDA

Entrada Therapeutics, Inc.

Healthcare · Biotechnology

$5.11

Down-$0.39 (-7.63%)

Updated Nov 3, 2026, 10:40 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
413.53M
P/E ratio
-4.34
Dividend yield
0.00%
52-week range
$4.11 – $16.45
Volume
653.04K
Avg. volume
275.51K

Price performance · TRDA

TRDA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

TRDA closed at $5.11 after 21 trading sessions, down 6.75% for the selected period.

Last close
$5.11
Period change
-6.75%
Period low
$4.37
Period high
$5.67
Daily close
View OHLC price history
TRDA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$4.58$5.13$4.43$5.11653.04K
Oct 30, 2026$4.37$4.55$4.255$4.535317.34K
Oct 29, 2026$4.87$5.07$4.35$4.40479.06K
Oct 28, 2026$4.38$4.88$4.33$4.84409.1K
Oct 27, 2026$4.72$4.85$4.35$4.41413.45K
Oct 26, 2026$4.52$4.945$4.46$4.75617.09K
Oct 23, 2026$4.67$4.695$4.385$4.41191.47K
Oct 22, 2026$4.71$4.78$4.555$4.73462.05K
Oct 21, 2026$5.02$5.035$4.60$4.65323.82K
Oct 20, 2026$4.81$5.27$4.79$4.99403.06K
Oct 19, 2026$4.36$4.84$4.27$4.82586.14K
Oct 16, 2026$4.79$4.85$4.345$4.37371.79K
Oct 15, 2026$4.52$4.96$4.425$4.78514.78K
Oct 14, 2026$4.69$4.77$4.1092$4.55740.06K
Oct 13, 2026$5.50$5.56$4.83$4.86255.25K
Oct 12, 2026$5.64$5.69$5.48$5.50198.62K
Oct 9, 2026$5.52$5.75$5.44$5.67209.36K
Oct 8, 2026$5.52$5.59$5.2501$5.53361.51K
Oct 7, 2026$5.33$5.66$5.30$5.61297.51K
Oct 6, 2026$5.52$5.52$5.25$5.42315.92K
Oct 5, 2026$5.38$5.48$5.15$5.48463.81K

Latest TRDA news

The latest Smart Investors Daily articles mentioning TRDA.

Stock researchCompany · Overview

TRDA research

Overview

Company profile and research snapshot.

Company profile

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.00
Implied upside
—
Analysts
11
TRDA recent ratings
DateFirmRatingTarget
Jun 8, 2026GuggenheimBuy—
May 8, 2026HC Wainwright & Co.Neutral—
Apr 6, 2026OppenheimerOutperform—
Feb 18, 2026HC Wainwright & Co.Buy—
Feb 11, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth Linea Aspesi Linea Aspesi BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Ex

Yahoo · Oct 14, 2026

What's Going On With Entrada Therapeutics Stock Wednesday?

On Wednesday, Entrada Therapeutics, Inc. (NASDAQ:TRDA) reported topline results from the first cohort of its Phase 1/2 ELEVATE-45-201 clinical trial. The study evaluates ENTR-601-45 in ambulatory patients who possess a Duchenne muscular dystrophy gene mutation suitable for exon 45 skipping. Following the announcement, the micro-cap biotech stock fell more than 15%. Future Clinical Milestones And Dosing Given the specific age of the participants, their baseline functional levels, and the short th

Yahoo · Oct 14, 2026

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and function

Yahoo · Oct 14, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascendin

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By